Insider Purchases: Inside the Buy
Tag: hub-insiders
🧗 VF Corporation (VFC): The North Face Pivot, a 92% Institutional Grip, and the 0.40 PEG Ratio Turnaround
After falling more than 80% from its peak, VF Corporation is quietly rebuilding. Insider buying, strong free cash flow, rapid deleveraging, and a 0.40 PEG ratio suggest the owner of The North Face, Vans, and Timberland may finally be finding its footing.
⚛️ Quantinuum (QNT): The $1.6B Quantum Leap, Insiders Loading at $60, and the Multiverse of Single-Digit Sales
Quantinuum's blockbuster IPO and $24 million insider-buying wave highlight the enormous promise—and equally enormous risks—of quantum computing. Revolutionary science, massive losses, and moonshot ambitions make QNT one of the market's most fascinating speculative bets.
🚀 Robinhood (HOOD): The $35M Insider Bet, the Great Wealth Transfer, and the Price of Fintech Dominance
Robinhood has evolved far beyond a commission-free trading app. With $307 billion in platform assets, 4.3 million Gold subscribers, and a $35 million insider purchase from fintech legend Meyer Malka, the company is increasingly positioning itself at the center of the next generation's financial lives.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.
🚀 Insperity (NSP): Why the CEO Just Bought Another $7.9M of This HR Stock
Insperity (NYSE: NSP) continues attracting major insider buying. CEO Paul Sarvadi has now purchased roughly $15.5 million of stock in less than three months, including a new $7.9 million purchase after shares rallied nearly 50%.
🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock
Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.
🧬 Annexon, Part 2: The $300,000 Guillain-Barré Cost Matrix and the Pipeline Fuse
Delve into the high-stakes financial and clinical reality of Guillain-Barré Syndrome (GBS)—a devastating neurological emergency carrying a brutal $300,000 cost of standard care. In Part 2 of our Annexon Biosciences (NASDAQ: ANNX) deep dive, we audit how their lead late-stage asset, Tanruprubart, targets C1q neuroinflammation at the source to completely upend healthcare economics, transform patient outcomes, and detonate an 11-day short squeeze trap.
1 comment
|
🌐 Globant (GLOB): The AI Infrastructure Tollbooth Trading at 7x Earnings
Globant (NYSE: GLOB) may be one of the most intriguing AI-related value plays on the market. Trading 87% below its peak, the company combines a growing AI-native services platform, accelerating cash flow, aggressive share buybacks, institutional ownership above 100% of float, and a historic first insider purchase from former Hong Kong Exchange CEO Alejandro Aguzin. Is Wall Street missing the story?
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.